Science to Practice: What Causes Arterial Infarction in Transforaminal Epidural Steroid Injections, and Which Steroid Is Safest?

Felix E. Diehn, Naveen S Murthy, Timothy Maus

Research output: Contribution to journalComment/debate

5 Citations (Scopus)

Abstract

Transforaminal epidural steroid injections (TFESIs) are associated with rare but devastating neurologic complications. Every published case has been associated with a particulate steroid suspension, and the presumed but not proven mechanism is embolization and occlusion of end arterioles. Through an in vivo murine model and in vitro experiments on human red blood cells (RBCs), the study by Laemmel et al (1) in this issue of Radiology elucidates the potential mechanisms for steroid-induced vascular compromise. Unlike dexamethasone (a nonparticulate steroid solution), saline, and the particulate steroid cortivazol, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) caused often immediate and complete cessation of capillary blood flow, with RBC (not steroid particle) aggregates and alteration of RBC morphologic structure into spiculated RBCs. Thus, the study strengthens evidence in support of the higher safety profile in TFESI for dexamethasone, the nonparticulate and U.S. Food and Drug Administration-recommended steroid of choice, compared with particulate steroids. The results should not be considered proof that cortivazol has not or could not cause neurologic infarction during a TFESI. Rather, experiments such as those by Laemmel et al should foster more research, particularly in the arena of novel therapeutic agents (nonparticulate steroids and nonsteroidal drugs alike).

Original languageEnglish (US)
Pages (from-to)657-659
Number of pages3
JournalRadiology
Volume279
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Epidural Injections
Infarction
Steroids
Erythrocytes
Dexamethasone
Nervous System
Triamcinolone
Methylprednisolone
Arterioles
United States Food and Drug Administration
Prednisolone
Radiology
Sodium Chloride
Blood Vessels
Suspensions

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Science to Practice : What Causes Arterial Infarction in Transforaminal Epidural Steroid Injections, and Which Steroid Is Safest? / Diehn, Felix E.; Murthy, Naveen S; Maus, Timothy.

In: Radiology, Vol. 279, No. 3, 01.06.2016, p. 657-659.

Research output: Contribution to journalComment/debate

@article{6a4349467bb645158b7e632613fb64db,
title = "Science to Practice: What Causes Arterial Infarction in Transforaminal Epidural Steroid Injections, and Which Steroid Is Safest?",
abstract = "Transforaminal epidural steroid injections (TFESIs) are associated with rare but devastating neurologic complications. Every published case has been associated with a particulate steroid suspension, and the presumed but not proven mechanism is embolization and occlusion of end arterioles. Through an in vivo murine model and in vitro experiments on human red blood cells (RBCs), the study by Laemmel et al (1) in this issue of Radiology elucidates the potential mechanisms for steroid-induced vascular compromise. Unlike dexamethasone (a nonparticulate steroid solution), saline, and the particulate steroid cortivazol, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) caused often immediate and complete cessation of capillary blood flow, with RBC (not steroid particle) aggregates and alteration of RBC morphologic structure into spiculated RBCs. Thus, the study strengthens evidence in support of the higher safety profile in TFESI for dexamethasone, the nonparticulate and U.S. Food and Drug Administration-recommended steroid of choice, compared with particulate steroids. The results should not be considered proof that cortivazol has not or could not cause neurologic infarction during a TFESI. Rather, experiments such as those by Laemmel et al should foster more research, particularly in the arena of novel therapeutic agents (nonparticulate steroids and nonsteroidal drugs alike).",
author = "Diehn, {Felix E.} and Murthy, {Naveen S} and Timothy Maus",
year = "2016",
month = "6",
day = "1",
doi = "10.1148/radiol.2016160171",
language = "English (US)",
volume = "279",
pages = "657--659",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Science to Practice

T2 - What Causes Arterial Infarction in Transforaminal Epidural Steroid Injections, and Which Steroid Is Safest?

AU - Diehn, Felix E.

AU - Murthy, Naveen S

AU - Maus, Timothy

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Transforaminal epidural steroid injections (TFESIs) are associated with rare but devastating neurologic complications. Every published case has been associated with a particulate steroid suspension, and the presumed but not proven mechanism is embolization and occlusion of end arterioles. Through an in vivo murine model and in vitro experiments on human red blood cells (RBCs), the study by Laemmel et al (1) in this issue of Radiology elucidates the potential mechanisms for steroid-induced vascular compromise. Unlike dexamethasone (a nonparticulate steroid solution), saline, and the particulate steroid cortivazol, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) caused often immediate and complete cessation of capillary blood flow, with RBC (not steroid particle) aggregates and alteration of RBC morphologic structure into spiculated RBCs. Thus, the study strengthens evidence in support of the higher safety profile in TFESI for dexamethasone, the nonparticulate and U.S. Food and Drug Administration-recommended steroid of choice, compared with particulate steroids. The results should not be considered proof that cortivazol has not or could not cause neurologic infarction during a TFESI. Rather, experiments such as those by Laemmel et al should foster more research, particularly in the arena of novel therapeutic agents (nonparticulate steroids and nonsteroidal drugs alike).

AB - Transforaminal epidural steroid injections (TFESIs) are associated with rare but devastating neurologic complications. Every published case has been associated with a particulate steroid suspension, and the presumed but not proven mechanism is embolization and occlusion of end arterioles. Through an in vivo murine model and in vitro experiments on human red blood cells (RBCs), the study by Laemmel et al (1) in this issue of Radiology elucidates the potential mechanisms for steroid-induced vascular compromise. Unlike dexamethasone (a nonparticulate steroid solution), saline, and the particulate steroid cortivazol, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) caused often immediate and complete cessation of capillary blood flow, with RBC (not steroid particle) aggregates and alteration of RBC morphologic structure into spiculated RBCs. Thus, the study strengthens evidence in support of the higher safety profile in TFESI for dexamethasone, the nonparticulate and U.S. Food and Drug Administration-recommended steroid of choice, compared with particulate steroids. The results should not be considered proof that cortivazol has not or could not cause neurologic infarction during a TFESI. Rather, experiments such as those by Laemmel et al should foster more research, particularly in the arena of novel therapeutic agents (nonparticulate steroids and nonsteroidal drugs alike).

UR - http://www.scopus.com/inward/record.url?scp=85021113097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021113097&partnerID=8YFLogxK

U2 - 10.1148/radiol.2016160171

DO - 10.1148/radiol.2016160171

M3 - Comment/debate

C2 - 27183400

AN - SCOPUS:85021113097

VL - 279

SP - 657

EP - 659

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -